Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 12 (April 20), 2008: pp. 1932-1939
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.13.8404

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, L.
Right arrow Articles by Relling, M. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, L.
Right arrow Articles by Relling, M. V.
Related Articles
Right arrowRelated Editorial
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia

Lei Yang, John C. Panetta, Xiangjun Cai, Wenjian Yang, Deqing Pei, Cheng Cheng, Nancy Kornegay, Ching-Hon Pui, Mary V. Relling

From the Departments of Pharmaceutical Sciences, Oncology, and Biostatistics, St Jude Children's Research Hospital; and the Colleges of Medicine and Pharmacy, University of Tennessee, Memphis, TN

Corresponding author: Mary V. Relling, PharmD, Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, 332 N Lauderdale, Memphis, TN 38105-2794; e-mail: mary.relling{at}stjude.org

Purpose Dexamethasone is used widely in oncology, but pharmacokinetic studies are lacking. We evaluated dexamethasone pharmacokinetics in children with acute lymphoblastic leukemia.

Patients and Methods We assessed 214 children with acute lymphoblastic leukemia who received 418 courses of oral dexamethasone (8 mg/m2/d) on days 1 and 8 of reinduction. Extensive asparaginase use preceded reinduction in the 101 children in the standard/high-risk treatment arm but not in the 113 children in the low-risk treatment arm. A one-compartment model with first-order absorption and disposition was fit to dexamethasone plasma concentrations by using maximum a posteriori probability estimation; we evaluated covariates by using linear mixed models.

Results Interpatient and intrapatient variabilities in apparent clearance were substantial; they were 46% and 53%, respectively. Variability was explained by the serum albumin concentration (P < .0001), concomitant use of fentanyl (P = .008) and ketoconazole (P = .03), and age (P = .006). Apparent clearance was higher in the low-risk arm (P < .001) and was related to a greater serum albumin concentration (P < .001) and to a lower exposure to asparaginase than in the standard/high-risk arm. Hypoalbuminemia, a biomarker of asparaginase activity, was associated with a lower dexamethasone apparent clearance (P = .04) in patients in the standard/high-risk arm that was more pronounced in those not allergic to asparaginase. Ethnicity or gender did not explain apparent clearance variability.

Conclusion Dexamethasone pharmacokinetics are highly variable and are related to the concurrent use of particular drugs, age, and treatment intensity. Patients allergic to asparaginase may be doubly disadvantaged: they not only suffer from diminished exposure to asparaginase but also, by maintaining high clearance of dexamethasone, may experience fewer antileukemic effects of dexamethasone.

Supported by Grants No. CA 51001 and CA 21765 from the National Institutes of Health, National Cancer Institute; by a Center of Excellence grant from the state of Tennessee; and by the American Lebanese Syrian Associated Charities. C.-H.P. is an American Cancer Society Professor.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • All Dex’ed Out With Nowhere to Go?
    Peter C. Adamson and Jeffrey S. Barrett
    JCO 2008 26: 1917-1918 [Full Text]


This article has been cited by other articles:


Home page
NEJMHome page
S. E. Sallan, M. Schrappe, L. B. Silverman, H. V. Naina, S. Harris, M. M. Patnaik, C.-H. Pui, K. Krull, and M. Relling
Treating childhood leukemia without cranial irradiation.
N. Engl. J. Med., September 24, 2009; 361(13): 1310 - 1311.
[Full Text] [PDF]


Home page
NEJMHome page
C.-H. Pui, D. Campana, D. Pei, W. P. Bowman, J. T. Sandlund, S. C. Kaste, R. C. Ribeiro, J. E. Rubnitz, S. C. Raimondi, M. Onciu, et al.
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
N. Engl. J. Med., June 25, 2009; 360(26): 2730 - 2741.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. C. Adamson and J. S. Barrett
All Dex'ed Out With Nowhere to Go?
J. Clin. Oncol., April 20, 2008; 26(12): 1917 - 1918.
[Full Text] [PDF]


Home page
ASH Education BookHome page
N. L. Seibel
Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents: Peaks and Pitfalls
Hematology, January 1, 2008; 2008(1): 374 - 380.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
A. Fielding
The Treatment of Adults with Acute Lymphoblastic Leukemia
Hematology, January 1, 2008; 2008(1): 381 - 389.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online